{"id":17347,"date":"2022-09-06T20:48:39","date_gmt":"2022-09-06T18:48:39","guid":{"rendered":"http:\/\/mabdesign.fr\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/"},"modified":"2022-09-06T20:48:39","modified_gmt":"2022-09-06T18:48:39","slug":"ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/","title":{"rendered":"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma"},"content":{"rendered":"

Paris, France, September 1st, 2022, 7:00 pm CET. <\/em><\/strong><\/p>\n

HEPHAISTOS-Pharma<\/a> a French Biotech company developing a new class of immunotherapies to address hard-to-treat and metastatic cancers, today announced that the European Commission granted Orphan Drug designation (ODD) to ONCO-Boost for the treatment of osteosarcoma.<\/p>\n

\u201cThis designation is an important milestone in the development of ONCO-Boost and demonstrate its potential clinical benefits for sarcoma patients who have an urgent need for effective, tolerable, and convenient treatment options\u201d said Fr\u00e9d\u00e9ric Caroff, CEO and co-founder of HEPHAISTOS-Pharma. \u201cThis key milestone was reached thanks to the collaboration of HEPHAISTOS-Pharma with the academic teams from Pr. Charles Dumontet at the Centre de Recherche contre le Cancer de Lyon (CRCL), and Pr. Jean-Yves Blay at the Centre L\u00e9on B\u00e9rard (CLB). These collaborations have demonstrated the potential clinical benefit of ONCO-Boost against sarcomas such as osteosarcoma and chondrosarcoma, but also against Lymphoma, colorectal and breast cancers. The company is now heading toward regulatory validation and expects a first clinical study by 2023.\u201d<\/p>\n

To know more<\/p>\n","protected":false},"excerpt":{"rendered":"

The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32,18],"tags":[],"class_list":["post-17347","post","type-post","status-publish","format-standard","hentry","category-news","category-our-members","category-uncategorized"],"yoast_head":"\nEMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma - MabDesign<\/title>\n<meta name=\"description\" content=\"The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma - MabDesign\" \/>\n<meta property=\"og:description\" content=\"The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-06T18:48:39+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma\",\"datePublished\":\"2022-09-06T18:48:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/\"},\"wordCount\":181,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/\",\"name\":\"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2022-09-06T18:48:39+00:00\",\"description\":\"The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma - MabDesign","description":"The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/","og_locale":"en_US","og_type":"article","og_title":"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma - MabDesign","og_description":"The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma.","og_url":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/","og_site_name":"MabDesign","article_published_time":"2022-09-06T18:48:39+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma","datePublished":"2022-09-06T18:48:39+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/"},"wordCount":181,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/","url":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/","name":"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2022-09-06T18:48:39+00:00","description":"The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/ema-has-granted-orphan-drug-designation-to-onco-boost-hephaistos-pharma-as-treatment-for-osteosarcoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"EMA has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=17347"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17347\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=17347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=17347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=17347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}